GE11 peptide conjugated selenium nanoparticles for EGFR targeted oridonin delivery to achieve enhanced anticancer efficacy by inhibiting EGFR-mediated PI3K/AKT and Ras/Raf/MEK/ERK pathways

References

• Adams JM. (2003). Ways of dying: multiple pathways to apoptosis. Genes Dev 17:2481–95.
   PubMed Web of Science ®Google Scholar
• Amin KA, Hashem KS, Alshehri FS, et al. (2016). Antioxidant and hepatoprotective efficiency of selenium nanoparticles against acetaminophen-induced hepatic damage. Biol Trace Elem Res 175:136–145.
   PubMed Web of Science ®Google Scholar
• Chen M, Chen R, Li Y, et al. (2011). Research and application in nanoparticle formulation of oridonin. Chin J Exp Trad Med Formulae 170:199–209.
   Google Scholar
• Cui Y, Dong C, Wu BQ, et al. (2015). Expression of cyclooxygenase-2, vascular endothelial growth factor, and epidermal growth factor receptor in Chinese patients with esophageal squamous cell carcinoma. J Can Res Ther 11:C44–8.
   PubMed Web of Science ®Google Scholar
• Dong Y, Zhang T, Li J, et al. (2014). Oridonin inhibits tumor growth and metastasis through anti-angiogenesis by blocking the Notch signaling. PLoS One 9:e113830.
   PubMed Web of Science ®Google Scholar
• Estevez H, Garcia-Lidon JC, Luque-Garcia JL, Camara C. (2014). Effects of chitosan-stabilized selenium nanoparticles on cell proliferation, apoptosis and cell cycle pattern in HepG2 cells: comparison with other selenospecies. Colloids Surf B Biointerfaces 122:184–93.
   PubMed Web of Science ®Google Scholar
• Fu X, Yang Y, Li X, et al. (2016). RGD peptide-conjugated selenium nanoparticles: antiangiogenesis by suppressing VEGF-VEGFR2-ERK/AKT pathway. Nanomedicine 12:1627–39.
   PubMed Web of Science ®Google Scholar
• Gao F, Yuan Q, Gao L, et al. (2014). Cytotoxicity and therapeutic effect of irinotecan combined with selenium nanoparticles. Biomaterials 35:8854–66.
   PubMed Web of Science ®Google Scholar
• Huang Y, He L, Liu W, et al. (2013). Selective cellular uptake and induction of apoptosis of cancer-targeted selenium nanoparticles. Biomaterials 34:7106–16.
   PubMed Web of Science ®Google Scholar
• Jiang W, Fu Y, Yang F, et al. (2014). Gracilaria lemaneiformis polysaccharide as integrin-targeting surface decorator of selenium nanoparticles to achieve enhanced anticancer efficacy. ACS Appl Mater Interfaces 6:13738–48.
   PubMed Web of Science ®Google Scholar
• Kong L, Yuan Q, Zhu H, et al. (2011). The suppression of prostate LNCaP cancer cells growth by selenium nanoparticles through Akt/Mdm2/AR controlled apoptosis. Biomaterials 32:6515–22.
   PubMed Web of Science ®Google Scholar
• Li CY, Wang EQ, Cheng Y, Bao JK. (2011a). Oridonin: an active diterpenoid targeting cell cycle arrest, apoptotic and autophagic pathways for cancer therapeutics. Int J Biochem Cell Biol 43:701–4.
   PubMed Web of Science ®Google Scholar
• Li Y, Li X, Wong YS, et al. (2011b). The reversal of cisplatin-induced nephrotoxicity by selenium nanoparticles functionalized with 11-mercapto-1-undecanol by inhibition of ROS-mediated apoptosis. Biomaterials 32:9068–76.
   PubMed Web of Science ®Google Scholar
• Li Y, Lin Z, Zhao M, et al. (2016). Multifunctional selenium nanoparticles as carriers of HSP70 siRNA to induce apoptosis of HepG2 cells. Int J Nanomedicine 11:3065–76.
   PubMed Web of Science ®Google Scholar
• Li Z, Zhao R, Wu X, et al. (2005). Identification and characterization of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of therapeutics. FASEB J 19:1978–85.
   PubMed Web of Science ®Google Scholar
• Liu JB, Yue JY. (2014). Preliminary study on the mechanism of oridonin-induced apoptosis in human squamous cell oesophageal carcinoma cell line EC9706. J Int Med Res 42:984–92.
   PubMed Web of Science ®Google Scholar
• Liu T, Zeng L, Jiang W, et al. (2015a). Rational design of cancer-targeted selenium nanoparticles to antagonize multidrug resistance in cancer cells. Nanomedicine 11:947–58.
   PubMed Web of Science ®Google Scholar
• Liu W, Li X, Wong YS, et al. (2012). Selenium nanoparticles as a carrier of 5-fluorouracil to achieve anticancer synergism. ACS Nano 6:6578–91.
   PubMed Web of Science ®Google Scholar
• Liu WT, Yang Y, Shen PH, et al. (2015b). Facile and simple preparation of pH-sensitive chitosan-mesoporous silica nanoparticles for future breast cancer treatment. Express Polym Lett 9:1068–75.
   Web of Science ®Google Scholar
• Lu J, Chen X, Qu S, et al. (2017). Oridonin induces G2/M cell cycle arrest and apoptosis via the PI3K/Akt signaling pathway in hormone-independent prostate cancer cells. Oncol Lett 13:2838–46.
   PubMed Web of Science ®Google Scholar
• Master AM, Qi Y, Oleinick NL, Gupta AS. (2012). EGFR-mediated intracellular delivery of Pc 4 nanoformulation for targeted photodynamic therapy of cancer: in vitro studies. Nanomedicine 8:655–64.
   PubMed Web of Science ®Google Scholar
• Mendelsohn J, Baselga J. (2000). The EGF receptor family as targets for cancer therapy. Oncogene 19:6550–65.
   PubMed Web of Science ®Google Scholar
• Mickler FM, Mockl L, Ruthardt N, et al. (2012). Tuning nanoparticle uptake: live-cell imaging reveals two distinct endocytosis mechanisms mediated by natural and artificial EGFR targeting ligand. Nano Lett 12:3417–23.
   PubMed Web of Science ®Google Scholar
• Nicholson KM, Anderson NG. (2002). The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 14:381–95.
   PubMed Web of Science ®Google Scholar
• Nicholson RI, Gee JM, Harper ME. (2001). EGFR and cancer prognosis. Eur J Cancer 37:S9–S15.
   PubMed Web of Science ®Google Scholar
• Pi J, Jin H, Jiang J, et al. (2017). Single molecule force spectroscopy for in-situ probing oridonin inhibited ROS-mediated EGF-EGFR interactions in living KYSE-150 cells. Pharmacol Res 119:479–89.
   PubMed Web of Science ®Google Scholar
• Pi J, Jin H, Liu R, et al. (2013). Pathway of cytotoxicity induced by folic acid modified selenium nanoparticles in MCF-7 cells. Appl Microbiol Biotechnol 97:1051–62.
   PubMed Web of Science ®Google Scholar
• Roovers K, Assoian RK. (2000). Integrating the MAP kinase signal into the G1 phase cell cycle machinery. Bioessays 22:818–26.
   PubMed Web of Science ®Google Scholar
• Salomon DS, Brandt R, Ciardiello F, Normanno N. (1995). Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19:183–232.
   PubMed Web of Science ®Google Scholar
• Shi Y. (2001). A structural view of mitochondria-mediated apoptosis. Nat Struct Biol 8:394–401.
   PubMedGoogle Scholar
• Sun D, Liu Y, Yu Q, et al. (2013). The effects of luminescent ruthenium(II) polypyridyl functionalized selenium nanoparticles on bFGF-induced angiogenesis and AKT/ERK signaling. Biomaterials 34:171–80.
   PubMed Web of Science ®Google Scholar
• Sun D, Liu Y, Yu Q, et al. (2014a). Inhibition of tumor growth and vasculature and fluorescence imaging using functionalized ruthenium-thiol protected selenium nanoparticles. Biomaterials 35:1572–83.
   PubMed Web of Science ®Google Scholar
• Sun T, Zhang YS, Pang B, et al. (2014b). Engineered nanoparticles for drug delivery in cancer therapy. Angew Chem Int Ed Engl 53:12320–64.
   PubMed Web of Science ®Google Scholar
• Wang H, Wei W, Zhang SY, et al. (2005). Melatonin-selenium nanoparticles inhibit oxidative stress and protect against hepatic injury induced by Bacillus Calmette-Guerin/lipopolysaccharide in mice. J Pineal Res 39:156–63.
   PubMed Web of Science ®Google Scholar
• Wang J, Yu JM, Jing SW, et al. (2014). Relationship between EGFR over-expression and clinicopathologic characteristics in squamous cell carcinoma of the esophagus: a meta-analysis. Asian Pac J Cancer Prev 15:5889–93.
   PubMedGoogle Scholar
• Wang L, Liu Y, Li W, et al. (2011). Selective targeting of gold nanorods at the mitochondria of cancer cells: implications for cancer therapy. Nano Lett 11:772–80.
   PubMed Web of Science ®Google Scholar
• Xu J, Gattacceca F, Amiji M. (2013). Biodistribution and pharmacokinetics of EGFR-targeted thiolated gelatin nanoparticles following systemic administration in pancreatic tumor-bearing mice. Mol Pharm10:2031–44.
   PubMed Web of Science ®Google Scholar
• Yu B, Zhang Y, Zheng W, et al. (2012a). Positive surface charge enhances selective cellular uptake and anticancer efficacy of selenium nanoparticles. Inorg Chem 51:8956–63.
   PubMed Web of Science ®Google Scholar
• Yu B, Zhang YB, Zheng WJ, et al. (2012b). Positive surface charge enhances selective cellular uptake and anticancer efficacy of selenium nanoparticles. Inorg Chem 51:8956–63.
   PubMed Web of Science ®Google Scholar
• Zhao CL, Ju JY, Gao W, et al. (2015). Downregulation of PLK1 by RNAi attenuates the tumorigenicity of esophageal squamous cell carcinoma cells via promoting apoptosis and inhibiting angiogenesis. Neoplasma 62:748–55.
   PubMed Web of Science ®Google Scholar
• Zhao Z, Chen Y. (2014). Oridonin, a promising antitumor natural product in the chemotherapy of hematological malignancies. Curr Pharm Biotechnol 15:1083–92.
   PubMed Web of Science ®Google Scholar
• Zhou FF, Xing D, Wu BY, et al. (2010). New Insights of transmembranal mechanism and subcellular localization of noncovalently modified single-walled carbon nanotubes. Nano Lett 10:1677–81.
   PubMed Web of Science ®Google Scholar